We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MOXIMED/ MOXIFLOXACIN/ MOXEZIN/ MOXIFLOXACIN B&B/ MOXIFLOXACIN MEDSURGE/ MOXIFLOXACIN MEDICIANZ (Micro Labs Pty Ltd)
Product name
MOXIMED/ MOXIFLOXACIN/ MOXEZIN/ MOXIFLOXACIN B&B/ MOXIFLOXACIN MEDSURGE/ MOXIFLOXACIN MEDICIANZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
92 (255 working days)
Active ingredients
moxifloxacin hydrochloride monohydrate
Registration type
New generic medicine
Indication
MOXIMED/ MOXIFLOXACIN/ MOXEZIN/ MOXIFLOXACIN B&B/ MOXIFLOXACIN MEDSURGE/ MOXIFLOXACIN MEDICIANZ tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions:
- Acute bacterial sinusitis
- Community acquired pneumonia
- Acute exacerbations of chronic bronchitis
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with MOXIMED/ MOXIFLOXACIN/ MOXEZIN/ MOXIFLOXACIN B&B/ MOXIFLOXACIN MEDSURGE/ MOXIFLOXACIN MEDICIANZ may be initiated, in some conditions, before results of these tests are known. Once results become available, therapy should be continued with the most appropriate antibiotic therapy.
Consideration should be given to available official guidance on the appropriate use of antibacterial agents.